Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565160 | 0.92 | PTGS2 (0.54) | PTGS2CYP51A1IDO1CYP19A1SCN9A | |
| SCHEMBL7561820 | 0.83 | PTGS2 (0.52) | PTGS2CYP51A1IDO1CYP19A1SCN9A | |
| SCHEMBL7563951 | 0.83 | PTGS2 (0.46) | PTGS2IDO1CYP19A1CYP3A4SMN1; SMN2 | |
| SCHEMBL7563092 | 0.80 | PTGS2 (0.52) | PTGS2CYP51A1IDO1CYP19A1CYP3A4 | |
| SCHEMBL7569922 | 0.79 | PTGS2 (0.47) | PTGS2CYP51A1IDO1CYP19A1CYP3A4 | |
| SCHEMBL7605941 | 0.77 | PTGS2 (0.46) | PTGS2CYP51A1CYP19A1CYP3A4CYP2C19 | |
| SCHEMBL7605945 | 0.77 | PTGS2 (0.48) | PTGS2CYP51A1CYP19A1SCN9ACYP3A4 | |
| SCHEMBL7561152 | 0.77 | FNTA (0.51) | PTGS2CYP51A1CYP3A4CYP2C19 | |
| SCHEMBL7862157 | 0.76 | FNTA (0.51) | PTGS2CYP51A1CYP3A4CYP2C19 | |
| SCHEMBL7563722 | 0.76 | FNTA (0.49) | PTGS2CYP51A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | PTGS2 2714/4885CYP51A1 75/4885IDO1 2422/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | PTGS2 2763/4885CYP51A1 107/4885IDO1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.